The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 11 of those trials with a site in Germany that also match the filters currently applied.
11 of the 2,500 most recently authorised trials in this register list a site in Germany and match the filters applied; 1 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
| Phase | Trials | Share |
|---|---|---|
| Phase II | 8 | 72.7% |
| Phase I | 2 | 18.2% |
| Phase III | 1 | 9.1% |
| Lead sponsor | Trials |
|---|---|
| Aclaris Therapeutics Inc. | 1 |
| Bluefin Biomedicine Inc. | 1 |
| Egle Therapeutics | 1 |
| Enveda Therapeutics Inc. | 1 |
| F. Hoffmann-La Roche AG | 1 |
| Incyte Corp. | 1 |
| Inmagene LLC | 1 |
| Novartis Pharma AG | 1 |
| Pfizer Inc. | 1 |
| Sitryx Therapeutics Limited | 1 |